24,437 Shares in Edwards Lifesciences Corporation $EW Purchased by AG2R LA Mondiale Gestion D Actifs

Key Points

• AG2R LA Mondiale Gestion D Actifs acquired 24,437 shares of Edwards Lifesciences Corporation, valued at approximately $1,911,000, during the first quarter as reported in a recent SEC filing.
• Insiders at Edwards Lifesciences have sold a total of 22,014 shares worth $1,698,844 over the last 90 days, with notable sales by Larry L. Wood and VP Daniel J. Lippis.
• Edwards Lifesciences reported $0.67 EPS in its last quarterly earnings, exceeding analysts' estimates, and set future EPS guidance for Q3 2025 between 0.540-0.60 EPS.

AG2R LA Mondiale Gestion D Actifs purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 24,437 shares of the medical research company's stock, valued at approximately $1,911,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. Quantbot Technologies LP bought a new position in Edwards Lifesciences during the first quarter valued at about $26,000. Vega Investment Solutions bought a new position in Edwards Lifesciences during the fourth quarter valued at about $27,000. SouthState Corp bought a new position in Edwards Lifesciences during the first quarter valued at about $27,000. Global X Japan Co. Ltd. increased its stake in Edwards Lifesciences by 116.1% during the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after acquiring an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC increased its stake in Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after acquiring an additional 205 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,014 shares of company stock worth $1,698,844. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Down 0.7%

NYSE EW opened at $77.50 on Friday. The firm has a market cap of $45.50 billion, a PE ratio of 11.15, a price-to-earnings-growth ratio of 3.76 and a beta of 1.07. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The stock's 50 day simple moving average is $78.92 and its 200 day simple moving average is $75.39. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Citigroup restated a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Dbs Bank upgraded Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Morgan Stanley upped their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Truist Financial upped their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research note on Friday, July 25th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $86.26.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.